Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21

Molecular Endocrinology

Volumn 11, Issue 1, 1997, Pages 54-66

  Musgrove, Elizabeth A ^a   Lee, Christine S L ^a   Cornish, Ann L ^a   Swarbrick, Alex ^a   Sutherland, Robert L ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; GESTAGEN; MIFEPRISTONE; PROGESTERONE RECEPTOR; PROTEIN P21;

ARTICLE; BREAST CANCER; CELL CYCLE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; ENZYME INHIBITION; GROWTH DISORDER; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 0031032142     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.11.1.9869     Document Type: Article

References (64)

1. Henderson BE, Ross RK, Pike MC 1991 Toward the primary prevention of cancer. Science 254:1131-1138
2. Early Breast Cancer Trialists' Collaborative Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1-15, 71-85
3. Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JGM 1989 Endocrine and antitumour effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumours. Endocrinology 125:1593-1598
4. Romieu G, Maudelonde T, Uhlmann A, Pujol H, Greiner J, Cavalie G, Khalaf S, Rochefort H 1987 The antiprogestin RU 486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 74:455
5. Klijn JGM, de Jong FH, Bakker GH, Lamberts SWJ, Rodenberg CJ, Alexieva-Figusch J 1989 Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49:2851-2856
6. Kloosterboer HJ, Deckers GH, Schoonen WGEJ 1994 Pharmacology of two new very selective antiprogestagens: ORG 31710 and ORG 31806. Hum Reprod 9[Suppl]1:47-52
7. Baulieu EE 1989 Contragestion and other clinical applications of RU 486, an antiprogesterone at the receptor. Science 245:1351-1357
8. Horwitz KB 1992 The molecular biology of RU 486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 13:146-163
9. Musgrove EA, Sutherland RL 1994 Cell cycle control by steroid hormones. In: Parker MG (ed) Seminars in Cancer Biology. Academic Press, London, pp 381-389
10. Watts CKW, Wilcken NRC, Hamilton JA, Sweeney KJE, Musgrove EA, Sutherland RL 1995 Mechanisms of antiestrogen, progestin/antiprogestin and retinoid inhibition of cell cycle progression in breast cancer cells. In: Pasqualini JP, Katzenellenbogen BS (eds) Hormone-Dependent Cancers. Molecular and Cellular Endocrinology. Marcel Dekker, New York, pp 119-140
11. Thomas M, Monet J-D 1992 Combined effects of RU 486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab 75:865-870
12. Musgrove EA, Sutherland RL 1993 Effects of the progestin antagonist RU 486 on T-47D cell cycle kinetics and cell cycle regulatory genes. Biochem Biophys Res Commun 195:1184-1190
13. 1. Breast Cancer Res Treat 17:155-156
14. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C 1995 Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 9:2364-2372
15. Sicinski P, Liu Donaher J, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RB, Elledge SJ, Weinberg RA 1995 Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630
16. Lyndon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Shyamala G, Conneely OM, O'Malley BW 1995 Mice lacking progesterone receptor exhibit pleiotrophic reproductive abnormalities. Genes Dev 9:2266-2278
17. Watts CKW, Brady A, Sarcevic B, deFazio A, Musgrove EA, Sutherland RL 1995 Antiestrogen inhibition of cell cycle progression in breast cancer cells is associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 9:1804-1813
18. Wilcken NRC, Sarcevic B, Musgrove EA, Sutherland RL 1996 Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. Cell Growth Differ 7:65-74
19. Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW, Sutherland RL 1993 Growth factor, steroid and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577-3587
20. Rhee K, Bresnahan W, Hirai M, Thompson EA 1995 c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation. Cancer Res 55:4188-4195
21. Morgan DO 1995 Principles of CDK regulation. Nature 374:131-134
22. Hunter T, Pines J 1991 Cyclins and cancer. Cell 66:1071-1074
23. Sherr CJ 1994 G1 phase progression: cycling on cue. Cell 79:551-555
24. Sherr CJ, Roberts JM 1995 Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163
25. Zhang H, Hannon GJ, Beach D 1994 p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 8:1750-1758
26. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai L-H, Zhang P, Dobrowlski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N 1995 Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400
27. Reynisdottir I, Polyak K, Iavarone A, Massagué J 1995 Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 9:1831-1845
28. Weinberg RA 1995 The retinoblastoma protein and cell cycle control. Cell 81:323-330
29. Lukas J, Müller H, Bartkova J, Spitkovsky D, Kjerulff AA, Jansen-Dürr P, Strauss M, Bartek J 1994 DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 125:625-638
30. 1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 15:2600-2611
31. Bartkova J, Lukas J, Müller H, Lützhøft D, Strauss M, Bartek J 1994 Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361
32. 1 to complete the cell cycle. Proc Natl Acad Sci USA 91:8022-8026
33. 1 phase in rodent fibroblasts. Genes Dev 7:1559-1571
34. 1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679
35. Musgrove EA, Sarcevic B, Sutherland RL 1996 Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for CDK2 activation and pRB hyperphosphorylation. J Cell Biochem 60:362-377
36. Sutherland RL, Hall RE, Pang GYN, Musgrove EA, Clarke CL 1988 Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells. Cancer Res 48:5084-5091
37. Deleted in proof
38. 1-arrested human breast cancer cells. Oncogene 12:2315-2324
39. Foster JS, Wimalasena J 1996 Estrogen regulated activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 10:488-498
40. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ 1993 The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816
41. Yang Z-Y, Perkinas ND, Ohno T, Nabel EG, Nabel GJ 1995 The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nature Med 1:1052-1056
42. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D 1993 p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704
43. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI 1994 p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023
44. 1. Genes Dev 7:812-821
45. 1-to-S phase transition. Mol Cell Biol 15:2612-2624
46. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL 1993 Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133
47. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G 1994 Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817
48. Bartkova J, Lukas J, Strauss M, Bartek J 1995 Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775-778
49. Hui R, Cornish AL, McClelland RA, Robertson JFR, Blarney RW, Musgrove EA, Nicholson RI, Sutherland RL 1996 Cyclin D1 and estrogen receptor gene expression are positively correlated in primary breast cancer. Clin Cancer Res 2:923-928
50. Dimri GP, Nakanishi M, Desprez P-Y, Smith JR, Campisi J 1996 Inhibition of E2F activity by the cyclin-dependent kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol Cell Biol 16:2987-2997
51. Shiyanov P, Bagchi S, Adami G, Kokontis J, Hay N, Arroyo M, Morozov A, Raychaudhuri P 1996 p21 disrupts the interaction between cdk2 and the E2F-p130 complex. Mol Cell Biol 16:737-744
52. Zhu L, Harlow E, Dynlacht BD 1995 p107 uses a p21 CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev 9:1740-1752
53. Shim J, Lee H, Park J, Kim H, Choi E-J 1996 A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 381:804-807
54. WAF1/CIP1 interacts with protein kinase CK2. Oncogene 13:391-398
55. Bardon S, Vignon F, Montcourrier P, Rochefort H 1987 Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. Cancer Res 47:1441-1448
56. Michna H, Schneider MR, Nishino Y, El Etreby MF 1989 Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies. Breast Cancer Res Treat 14:275-288
57. Shao Z-M, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han Q-X, Ordonex JV, Shroot B, Fontana JA 1995 p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11:493-504
58. WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast cancer cell lines. Oncogene 11:1899-1905
59. Musgrove EA, Wakeling AE, Sutherland RL 1989 Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res 49:2398-2404
60. El-Deiry WS, Tokino T, Velculesco VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
61. Margolis B, Rhee SG, Felder S, Mervic M, Lyall R, Levitski A, Ullrich A, Zilberstein A, Schlessinger J 1989 EGF induced tyrosine phosphorylation of phospholipase C-II: A potential mechanism for EGF receptor signaling. Cell 57:1101-1107
62. Harlow E, Lane D 1988 Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, p 726
63. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato J-Y 1994 D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066-2076
64. 1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14:2077-2086